Jazz Pharmaceuticals

121.26
0.08 (0.07%)
At close: Jan 21, 2025, 3:59 PM
121.43
0.14%
After-hours Jan 21, 2025, 04:00 PM EST

Jazz Pharmaceuticals Revenue Breakdown

Quarter Sep 30, 2024Jun 30, 2024Mar 31, 2024Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016Dec 31, 2015Sep 30, 2015Jun 30, 2015Mar 31, 2015Dec 31, 2014Sep 30, 2014Jun 30, 2014Mar 31, 2014Dec 31, 2013Sep 30, 2013Jun 30, 2013Mar 31, 2013Dec 31, 2012Sep 30, 2012Jun 30, 2012Mar 31, 2012
Defitelio/Defibrotide Revenue 65.82M 45.42M 47.68M 46.11M 39.08M 40.65M 49.45M 54.70M 49.49M 42.51M 57.70M 48.10M 49.62M 55.45M 50.24M 42.71M 47.43M 47.78M 37.60M 46.05M 41.50M 37.71M 36.18M 4.00M 6.03M 3.44M 6.07M 6.71M 6.35M 8.10M 251.75M 242.90M 247.85M 212.69M 222.50M 204.34M 191.37M 160.38M 164.18M 153.66M 133.74M 117.53M 113.51M 102.61M 89.10M 73.44M
Defitelio/Defibrotide Revenue Growth +44.91% -4.73% +3.40% +17.99% -3.87% -17.79% -9.59% +10.52% +16.41% -26.33% +19.98% -3.07% -10.52% +10.38% +17.62% -9.95% -0.73% +27.06% -18.35% +10.98% +10.04% +4.24% +803.52% -33.58% +75.49% -43.37% -9.61% +5.73% -21.65% -96.78% +3.64% -2.00% +16.53% -4.41% +8.89% +6.78% +19.32% -2.32% +6.84% +14.90% +13.80% +3.53% +10.62% +15.17% +21.32% n/a
Epidiolex/Epidyolex Revenue 251.56M 247.10M 198.72M 202.23M 188.91M 207.00M 196.22M 175.29M 157.89M 193.79M 160.38M 109.48M 2.78M 1.60M 1.87M 852.00K 2.52M 4.23M 4.48M 5.17M 3.67M 4.91M 3.81M 27.95M 26.23M 24.07M 9.72M 298.03M 272.33M 291.20M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Epidiolex/Epidyolex Revenue Growth +1.80% +24.35% -1.74% +7.05% -8.74% +5.49% +11.94% +11.02% -18.52% +20.83% +46.49% +3833.92% +74.37% -14.74% +119.72% -66.22% -40.34% -5.67% -13.36% +40.85% -25.20% +29.01% -86.39% +6.57% +8.96% +147.67% -96.74% +9.44% -6.48% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Other Products Revenue 2.23M 2.70M 3.57M 3.42M 3.43M 3.07M 1.00M 1.63M 943.00K 1.03M 3.34M 2.64M 603.53M 661.30M 596.95M 26.57M 32.72M 31.52M 29.58M 31.36M 28.94M 25.62M 21.04M 356.01M 316.78M 312.48M 303.87M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Other Products Revenue Growth -17.38% -24.43% +4.48% -0.50% +11.97% +206.39% -38.66% +73.06% -8.45% -69.20% +26.62% -99.56% -8.74% +10.78% +2146.87% -18.80% +3.80% +6.56% -5.68% +8.36% +12.98% +21.77% -94.09% +12.38% +1.38% +2.83% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Product And Services, Product Sales Net Of Deductions Revenue 989.71M 964.14M 842.10M 946.99M 884.22M 967.53M 935.77M 928.30M 809.84M 892.88M 834.25M 748.34M 33.16M 30.99M 30.82M 446.81M 407.88M 435.35M 425.64M 413.21M 368.32M 374.83M 357.25M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Product And Services, Product Sales Net Of Deductions Revenue Growth +2.65% +14.49% -11.08% +7.10% -8.61% +3.39% +0.80% +14.63% -9.30% +7.03% +11.48% +2157.10% +6.98% +0.54% -93.10% +9.55% -6.31% +2.28% +3.01% +12.19% -1.74% +4.92% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Sativex Revenue 4.59M 6.38M 2.73M 2.81M 7.10M 4.72M 3.22M 4.14M 4.74M 4.65M 6.10M 1.96M 335.55M 439.27M 447.81M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Sativex Revenue Growth -28.15% +133.38% -2.53% -60.47% +50.35% +46.61% -22.26% -12.65% +2.00% -23.75% +210.91% -99.42% -23.61% -1.91% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Total Oncology Revenue 284.75M 277.31M 257.55M 252.21M 228.89M 30.27M 30.07M 33.89M 33.76M 34.76M 34.69M 31.45M 75.42M 53.44M 36.94M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Total Oncology Revenue Growth +2.68% +7.67% +2.12% +10.19% +656.25% +0.66% -11.28% +0.39% -2.90% +0.22% +10.29% -58.29% +41.13% +44.66% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Vyxeos Revenue 34.31M 43.01M 32.02M 34.06M 36.70M 247.50M 256.04M 269.42M 247.50M 288.76M 307.33M 334.18M 54.33M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Vyxeos Revenue Growth -20.22% +34.32% -5.97% -7.20% -85.17% -3.34% -4.97% +8.86% -14.29% -6.04% -8.03% +515.05% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Xyrem Revenue 58.11M 62.18M 64.23M 159.77M 178.13M 281.38M 255.94M 235.03M 186.08M 182.65M 153.06M 124.16M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Xyrem Revenue Growth -6.54% -3.19% -59.80% -10.31% -36.70% +9.94% +8.90% +26.30% +1.88% +19.33% +23.27% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Xywav Revenue 388.47M 368.47M 315.30M 326.56M 277.76M 71.97M 70.32M 68.28M 59.34M 64.84M 71.71M 55.92M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Xywav Revenue Growth +5.43% +16.86% -3.45% +17.57% +285.95% +2.34% +2.98% +15.08% -8.48% -9.59% +28.23% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Zepzelca Revenue 85.84M 81.05M 75.10M 70.35M 67.18M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Zepzelca Revenue Growth +5.92% +7.92% +6.75% +4.71% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

Revenue by Geography

Quarter Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016Dec 31, 2015Dec 31, 2014Dec 31, 2013Dec 31, 2012Dec 31, 2011
Europe Revenue 239.64M 230.16M 175.21M 150.20M 125.91M 122.79M 106.15M 103.61M 126.72M 61.84M 38.59M 6.22M
Europe Revenue Growth +4.12% +31.36% +16.65% +19.29% +2.54% +15.68% +2.44% -18.23% +104.90% +60.26% +520.02% n/a
Other Countries Revenue 49.36M 43.84M 43.82M 46.24M 37.44M 32.45M 26.91M 28.31M 1.01B 792.52M n/a n/a
Other Countries Revenue Growth +12.59% +0.05% -5.24% +23.53% +15.37% +20.59% -4.96% -97.19% +27.11% n/a n/a n/a
United States Revenue 3.37B 2.82B 2.14B 1.97B 1.73B 1.46B 1.35B 1.19B n/a n/a n/a n/a
United States Revenue Growth +19.51% +31.51% +9.12% +13.76% +18.05% +8.01% +13.58% n/a n/a n/a n/a n/a

Operating Expense Breakdown

Quarter Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016Sep 30, 2016Jun 30, 2016Mar 31, 2016Dec 31, 2015Sep 30, 2015Jun 30, 2015Mar 31, 2015
Selling, General, and Administrative Revenue 325.77M 338.52M 351.71M 334.31M 308.31M 340.84M 297.92M 383.20M 358.48M 366.47M 308.81M 398.46M 363.68M 429.03M 260.51M 247.17M 207.25M 191.41M 208.40M 214.28M 178.71M 176.01M 167.95M 161.87M 155.87M 158.58M 207.21M 143.05M 124.52M 132.33M 144.25M 127.14M 124.37M 122.62M 128.76M 125.56M 104.04M 107.13M 112.39M
Selling, General, and Administrative Revenue Growth -3.77% -3.75% +5.21% +8.43% -9.55% +14.41% -22.26% +6.90% -2.18% +18.67% -22.50% +9.56% -15.23% +64.69% +5.40% +19.26% +8.28% -8.15% -2.74% +19.90% +1.53% +4.80% +3.76% +3.84% -1.71% -23.47% +44.85% +14.88% -5.90% -8.27% +13.46% +2.23% +1.43% -4.77% +2.56% +20.67% -2.88% -4.68% n/a
Research and Development Revenue 199.92M 220.73M 222.85M 216.61M 234.40M 209.24M 189.41M 172.56M 148.87M 139.05M 129.98M 155.44M 141.04M 132.70M 76.57M 91.70M 78.65M 78.92M 86.11M 97.38M 79.86M 62.38M 60.10M 56.66M 51.16M 56.13M 62.67M 66.00M 47.36M 40.16M 44.93M 44.16M 47.80M 39.09M 31.25M 29.45M 50.78M 27.83M 27.18M
Research and Development Revenue Growth -9.43% -0.95% +2.88% -7.59% +12.03% +10.47% +9.77% +15.91% +7.06% +6.97% -16.38% +10.22% +6.29% +73.29% -16.50% +16.60% -0.35% -8.34% -11.58% +21.95% +28.01% +3.79% +6.09% +10.74% -8.86% -10.43% -5.04% +39.34% +17.94% -10.62% +1.74% -7.61% +22.27% +25.08% +6.10% -42.00% +82.46% +2.40% n/a